|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.720 USD | -6.53% |
|
+9.68% | +98.54% |
| Mar. 22 | Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index | CI |
| Mar. 13 | Allogene Therapeutics, Inc., Q4 2025 Earnings Call, Mar 12, 2026 |
Evolution of the Average Target: Allogene Therapeutics, Inc.
Evolution of the Target Price: Allogene Therapeutics, Inc.
Changes in Analyst Recommendations: Allogene Therapeutics, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +168.38% | |||||
| +23.35% | |||||
| +26.61% | |||||
| +37.04% | |||||
| +38.68% | |||||
| +26.43% | |||||
| +24.72% | |||||
| +25.62% | |||||
| +54.25% | |||||
| +8.16% | |||||
| Average | +43.32% | |||||
| Weighted average by Cap. | +29.43% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| UBS | |
| JPMorgan Chase | |
| RBC Capital Markets | |
| Oppenheimer | |
| Truist Securities | |
| Piper Sandler | |
| HC Wainwright | |
| Stifel Nicolaus | |
| B. Riley | |
| JMP Securities | |
| Citigroup | |
| Bernstein | |
| Goldman Sachs | |
| Baird | |
| EF Hutton | |
| BofA Securities | |
| Raymond James | |
| Guggenheim | |
| Cowen | |
| SMBC Nikko | |
| Roth Capital Partners | |
| Jefferies & Co. |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALLO Stock
- Consensus Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
